Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Obstetricians/Gynecologists (US)

John Spurlock, MD, Medical Director
John Spurlock, MD, Medical Director
Continence Management Institute of the LeHigh Valley
Analysis of: Infection Cuts Pregnancy Rates With In-Vitro Fertilization (www.medscape.com)
1. Most women of reproductive age have HPV; therefore, most women undergoing invitro fertilization have HPV.2. I do not believe in vitro rates will decrease.3. News should boost Gardasil use!4. Should boost rates of In Vitro
John Spurlock, MD, Medical Director
John Spurlock, MD, Medical Director
Continence Management Institute of the LeHigh Valley
Analysis of: HPV DNA Testing Likely to Become Primary Cervical Cancer Screening Tool as Vaccine Use Expands, Predict International Experts (www.medicalnewstoday.com)
1. Digene should corner the market for HPV testing.2. HPV testing will become mandatory with introduction of HPV vaccines.3. Mutations should not be a problem for Digene.
John Spurlock, MD, Medical Director
John Spurlock, MD, Medical Director
Continence Management Institute of the LeHigh Valley
Analysis of: Innocoll's collagen wound care product approved by FDA (www.pipelinereview.com)
1.CollaGUARD should be a significant improvement over existing products for wound care.2.CollaGUARD is a profitable addition to the billion dollar wound care market.3.CollaGUARD may be superior to Regranex.
John Spurlock, MD, Medical Director
John Spurlock, MD, Medical Director
Continence Management Institute of the LeHigh Valley
Analysis of: McGuire is out at UnitedHealth: Hemsley in as CEO, board shuffled after options timing probe (www.chicagotribune.com)
1. New CEO Hemsley should improve UnitedHealth's profits2. The exit of McGuire should be good for UnitedHealth
John Spurlock, MD, Medical Director
John Spurlock, MD, Medical Director
Continence Management Institute of the LeHigh Valley
Analysis of: Fondaparinux Sodium Granted Priority Review (www.ptcommunity.com)
1. Fondaparinux Sodium is a new class of agents in the war against thrombosis. 2. Fondaparinux Sodium should achieve significant sales in the short term. 3. Fondaparinux Sodium is possibly superior to present agents, such as Plavix
John Spurlock, MD, Medical Director
John Spurlock, MD, Medical Director
Continence Management Institute of the LeHigh Valley
Analysis of: Æterna Zentaris Announces Positive Phase 2 Results for Ozarelix in Benign Prostatic Hyperplasia (www.pipelinereview.com)
1. Ozarelix is a revolutionary new medication for the treatment of benign prostatic hypertrophy.2. Ozarelix should replace current formulary medications for BPH3. Ozarelix is a significant improvement over GNRH agonists which have significant side effects.

Previous Page : 1 2 3 431 to 36 of 36

Analytics


Generated at 2009-01-07T19:00:58.307